Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Update

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF - Get Free Report) saw a significant drop in short interest in January. As of January 31st, there was short interest totalling 642,400 shares, a drop of 55.7% from the January 15th total of 1,450,700 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 6,424.0 days.

Wall Street Analysts Forecast Growth

Separately, Barclays upgraded Swedish Orphan Biovitrum AB (publ) to a "strong-buy" rating in a research note on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Stock Performance

OTCMKTS BIOVF remained flat at $30.48 during trading on Monday. The firm has a market cap of $10.85 billion, a PE ratio of 51.66 and a beta of 0.53. The business's fifty day moving average is $28.73 and its 200-day moving average is $28.86. The company has a current ratio of 0.73, a quick ratio of 0.49 and a debt-to-equity ratio of 0.30. Swedish Orphan Biovitrum AB has a 12 month low of $22.87 and a 12 month high of $32.25.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.